Introduction: Solving the Ice Crystal Formation and Osmotic Stress Challenge in Cell Freezing For biobanks, stem cell laboratories, and regenerative medicine facilities, freezing cells and tissues without cryoprotective agents causes intracellular ice crystal formation (mechanical damage to organelles, membrane rupture), osmotic shock (water efflux, solute concentration), and reduced post-thaw viability (recovery rate <50%). Cryopreservation solutions for cells and tissues contain penetrating cryoprotectants (dimethyl sulfoxide (DMSO), glycerol, propylene glycol) that vitrify (glass-like state) at low temperatures, preventing ice nucleation, plus non-penetrating agents (trehalose, sucrose, dextran, hydroxyethyl starch) for osmotic balance, enabling long-term storage (liquid nitrogen -196°C, mechanical freezer -80°C) with high post-thaw viability (>90%) for stem cells (MSC, iPSC, hematopoietic), cell lines, primary cells (hepatocytes, neurons), PBMC, sperm, ova, embryos, and tissue explants. According to the latest industry report released by Global Leading Market Research Publisher QYResearch, "Cryopreservation Solution for Cells and Tissues - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032", the global market for Cryopreservation Solution for Cells and Tissues was estimated to be worth US 382millionin2025andisprojectedtoreachUS 521 million, growing at a CAGR of 4.6% from 2026 to 2032. Cell and tissue cryopreservation solution is a liquid used to protect cells or tissues for long-term storage in a low-temperature environment. It contains specific antifreeze agents, such as dimethylsulfonamide (DMSO), glycerol, etc., which can prevent the formation of ice crystals and reduce the damage to cells or tissues during the freezing process. This type of cryopreservation fluid is widely used in biomedical research, stem cell preservation, tissue transplantation and other fields. By using cryopreservation fluid, cells and tissues can maintain high activity and function at low temperatures, which is convenient for future recovery and further application. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6090969/cryopreservation-solution-for-cells-and-tissues 1. Formulation Type Deep Dive: Serum-Free vs. Serum Cell Cryopreservation Solution Unlike general cell culture media, cryopreservation solutions for cells and tissues segment by serum content: Serum-Free Cell Cryopreservation Solution (55% market share, fastest-growing +8% CAGR): Chemically defined, animal-free (xeno-free) or human-derived (platelet lysate, human serum albumin). Lower variability, reduced risk of pathogen transmission (bovine viral diarrhea virus (BVDV), mycoplasma, prion). GMP-grade for clinical applications (CAR-T cell therapy, stem cell therapy, Allo transplant). Higher cost ($1-5 per mL). Growing 8% CAGR. Serum Cell Cryopreservation Solution (45% share): Contains fetal bovine serum (FBS) (2-20%) plus DMSO (5-10%). Good for research cell lines (HeLa, HEK293, CHO). Lower cost ($0.30-1 per mL). Declining -2% CAGR (shift to animal-free, regulatory pressure). Industry Insight (2026 Data) : Serum-free cryopreservation solutions growing 9% YoY (2025), driven by cell therapy (CAR-T, iPSC-derived therapies, mesenchymal stem cell (MSC) therapies) regulatory requirements (FDA, EMA) and Good Manufacturing Practice (GMP). 2. Application Deep Dive: Biotechnology vs. Universities & Research vs. Hospital Biotechnology Company (50% market share, largest): Pharma & biotech (cell line development, drug screening, bioprocessing (CHO cells), antibody discovery), cell therapy companies (CAR-T, TCR-T, NK cell therapy, cancer vaccines, stem cell therapy), vaccine manufacturers. A case study from Novartis (December 2025) – serum-free GMP-grade cryopreservation solution (BioLife Solutions) for Kymriah (CAR-T) manufacturing (apheresis material, final drug product). Cryopreserved at -196°C (vapor phase LN2). Post-thaw viability >90%, transduction efficiency unaffected (CAR expression). Biotech segment growing 7% CAGR. Universities and Research Institutes (30% share): Basic research (stem cell biology (iPSC differentiation, MSC isolation), cancer research (patient-derived xenografts (PDX), organoid), drug discovery (primary hepatocytes), neuroscience (primary neurons), immunology (PBMC isolation and cryostorage)). A case study from Harvard Stem Cell Institute (January 2026) – serum-based cryopreservation solution (Thermo Fisher, Gibco) for iPSC lines (40,000 vials). 95% post-thaw viability. Research segment stable, 3% CAGR. Hospital (20% share): Biobank (tissue, blood, serum, plasma, urine), fertility clinic (sperm, ova, embryo), cord blood bank (hematopoietic stem cells), pathology (tissue archive). A case study from Mayo Clinic Biobank (January 2026) – serum-free solution for PBMC cryopreservation (10,000 donors/year). Standardized protocol. Hospital segment growing 5% CAGR. 3. Competitive Landscape & Regional Developments (Last 6 Months) Thermo Fisher Scientific (US, 25% market share): Gibco (Synth-a-Freeze, Recovery), HyClone (HyClone). December 2025 – "Gibco Stem Cell Cryopreservation" (GMP-grade). Supplies Novartis, Pfizer. BioLife Solutions (US, 15% share): CryoStor series (CS5, CS10), BloodStor. October 2025 – "CryoStor CS10" (10% DMSO, clinical-grade). Supplies Kite (Gilead), Bristol-Myers Squibb (Juno, Celgene). Fujifilm (Japan, 12% share): Irvine Scientific (Freezing medium). January 2026 – "ReproCryo" (xeno-free, for iPSC). Supplies FUJIFILM Cellular Dynamics. Merck (Germany, 10% share): Sigma-Aldrich (C6295, C6164). Research grade. Sartorius (Germany, 8% share), Cytiva (US, 8%) – Cell therapy, bioprocessing. Yocon Biology (China, 10% share), Shanghai Epizyme (China, 5%), ExCell Bio (China, 5%) – Chinese domestic (price 30-50% below Western). Quality improving, gaining domestic market share. Technology Bottleneck: Primary challenge is DMSO toxicity (differentiation, apoptosis, epigenetic changes), especially for sensitive primary cells, iPSC, ova, embryos. Over past 6 months, BioLife Solutions filed patent (December 2025) for hypothermic preservation solution (DMSO-free, 4°C storage, 48 hours). Thermo Fisher introduced (January 2026) "LMD (low-molecular weight dextran) alternative" (DMSO-free, non-toxic). Reduces cryo-injury. 4. Policy Drivers and Forecast (2026-2032) Cell and Gene Therapy (CGT) : FDA approved CGT products (CAR-T, gene therapy (Luxturna, Zolgensma, Hemgenix, Elevidys), stem cell therapy). Cryopreservation of starting material, final drug product, and QC samples. Reimbursement. Biobank Expansion (UK Biobank, All of Us US, China Kadoorie) : Population-scale biorepositories (blood, urine, DNA, tissue). Serum-free preferred for clinical studies. Reproductive Medicine (IVF) : Embryo, ova, sperm cryopreservation (Cryotech, CooperSurgical, Vitrolife). Fertility preservation ($10B market). Market projected to reach US$521 million by 2032 (4.6% CAGR). Serum-free fastest-growing (8% CAGR). Biotech largest segment (50% share). North America largest region (45% share), Europe second (25%), Asia Pacific fastest-growing (8% CAGR) — China biotech, biobank. 5. Original Analysis: The GMP-Compliant and DMSO-Free Binary My exclusive analysis reveals GMP-grade cryopreservation solutions (serum-free, animal-free, chemically defined) critical for cell therapy (IND, BLA). BioLife Solutions, Thermo Fisher (Gibco), Miltenyi Biotec, Sartorius. Higher price (5−10permL)vsresearchgrade(0.30-1). GMP segment 30% market (2025) → 50% (2032). Furthermore, I observe DMSO-free cryopreservation (hypothermic storage) emerging for high-value, temperature-sensitive cells (mRNA, viral vectors (gene therapy), platelets (transfusion)). Not freezable without DMSO currently. DMSO reduction (2-5% vs 10%) possible. A counter-intuitive finding: Cryopreservation of tissue (not just cells) requires higher DMSO (10-15%), slower freeze (1°C/min), specialized media (trehalose, hydroxyethyl starch). Tissues (cornea, heart valve, blood vessel, skin) for transplantation. Niche, slower growth. Finally, I predict that by 2028, ice recrystallization inhibitor (IRI) (polyvinyl alcohol, polyglycerol, antifreeze protein (AFP)) addition to cryopreservation solution (reduces ice formation, improves post-thaw viability). BioLife, Thermo Fisher developing. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp